cAMP response element–binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation

Approximately 90% of human ovarian tumors result from transformation of ovarian surface epithelial cells. It has been hypothesized that repeated destruction of the epithelial cells during ovulation, followed by proliferation and migration of epithelial cells to restore the ovarian surface, renders these cells susceptible to mutagenic events. One of the proteins found to promote ovarian surface epithelial cell survival and proliferation was the transcription factor, cAMP response element–binding protein (CREB). Thus, the objective of this study was to determine whether CREB was also highly expressed in tumor cells originating from the ovarian epithelium. Using an ovarian cancer tissue array, it was observed that approximately 54% of the epithelial-derived human ovarian tumors displayed moderate or high levels of CREB immunostaining, while none of the normal ovarian samples did. Comparison of CREB levels in a human ovarian tumor cell line to those of a normal ovarian epithelial cell line revealed elevated levels of CREB and phosphorylated CREB in the ovarian tumor cells. To determine whether CREB regulated proliferation and/or apoptosis in the ovarian tumor cell line, CREB expression was suppressed using RNA interference. Decreased CREB expression significantly reduced ovarian tumor cell proliferation, while there was no effect on apoptosis in these cells. Finally, we showed that CREB is highly expressed in an in vivo murine model of ovarian tumorigenesis. Therefore, CREB is frequently overexpressed in ovarian cancer where it appears to promote cell proliferation.

[1]  G. Thomas,et al.  EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts , 1993, Nature Genetics.

[2]  P. Humphrey,et al.  Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. , 1993, Obstetrics and gynecology.

[3]  D. Ginty,et al.  Function and Regulation of CREB Family Transcription Factors in the Nervous System , 2002, Neuron.

[4]  A. Herbst The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. , 1994, American journal of obstetrics and gynecology.

[5]  I. Verma,et al.  CREB represses transcription of fos promoter: role of phosphorylation. , 1991, Gene expression.

[6]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[7]  J. Fata,et al.  Inhibition of mammary epithelial apoptosis and sustained phosphorylation of Akt/PKB in MMTV-IGF-II transgenic mice , 2001, Cell Death and Differentiation.

[8]  H. Giebler,et al.  Binding of p53 to the KIX Domain of CREB Binding Protein , 1999, The Journal of Biological Chemistry.

[9]  A. Zeleznik,et al.  cAMP response element-binding (CREB) signalling and ovarian surface epithelial cell survival. , 2006, The Journal of endocrinology.

[10]  M. Bar‐eli,et al.  Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family , 2000, Molecular and Cellular Biochemistry.

[11]  Richard G. Jenner,et al.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Birrer,et al.  p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. , 1993, Cancer research.

[13]  S. Bhatia,et al.  Expression of cyclic adenosine monophosphate response-element binding protein in acute leukemia. , 2002, Blood.

[14]  S. Nicosia,et al.  Growth effects of protein hormones on cultured rabbit ovarian surface epithelial cells. , 1985, Biology of reproduction.

[15]  I. Konishi,et al.  Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. , 1998, Human pathology.

[16]  A. Godwin,et al.  Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. , 1994, Cancer research.

[17]  R. Scully,et al.  Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. , 2007, DNA repair.

[18]  P. Shaw,et al.  Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. , 2008, Gynecologic oncology.

[19]  K. Sakamoto,et al.  The Role of Cyclic-AMP Binding Protein (CREB) in Leukemia Cell Proliferation and Acute Leukemias , 2004, Leukemia & lymphoma.

[20]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[21]  R. Scully,et al.  p53 expression in ovarian borderline tumors and stage I carcinomas. , 1994, American journal of clinical pathology.

[22]  U. Moens,et al.  What turns CREB on? , 2004, Cellular signalling.

[23]  R. Moorehead,et al.  IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells , 2005, Oncogene.

[24]  H. Giebler,et al.  p53 Recruitment of CREB Binding Protein Mediated through Phosphorylated CREB: a Novel Pathway of Tumor Suppressor Regulation , 2000, Molecular and Cellular Biology.

[25]  A. Villanueva,et al.  K‐ras mutations in mucinous ovarian tumors , 1997, Cancer.

[26]  S. Mok,et al.  The biology of ovarian cancer. , 1998, Seminars in oncology.

[27]  A. Godwin,et al.  Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. , 1992, Journal of the National Cancer Institute.

[28]  R. Berkowitz,et al.  p53 gene mutation in human borderline epithelial ovarian tumors. , 1994, Journal of the National Cancer Institute.

[29]  S. Gayther,et al.  Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention , 2006, Acta obstetricia et gynecologica Scandinavica.

[30]  D. McConkey,et al.  CREB and Its Associated Proteins Act as Survival Factors for Human Melanoma Cells* , 1998, The Journal of Biological Chemistry.

[31]  R. Berkowitz,et al.  k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[32]  R. Berkowitz,et al.  Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. , 2000, The American journal of pathology.

[33]  R. Maldonado,et al.  Genetic analysis of drug addiction: the role of cAMP response element binding protein , 1998, Journal of Molecular Medicine.

[34]  F. Couch,et al.  CBP truncating mutations in ovarian cancer , 2005, Journal of Medical Genetics.

[35]  Takashi Tsuruo,et al.  Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling , 2005, Oncogene.

[36]  M. Hagiwara,et al.  Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB , 1992, Cell.

[37]  Gideon Rechavi,et al.  A Pivotal Role of Cyclic AMP-Responsive Element Binding Protein in Tumor Progression , 2004, Cancer Research.

[38]  N. Auersperg,et al.  Ovarian carcinogenesis and the biology of ovarian surface epithelium , 1997, Journal of cellular physiology.

[39]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.

[40]  Edward C Stites,et al.  Network Analysis of Oncogenic Ras Activation in Cancer , 2007, Science.

[41]  R. Baserga,et al.  Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth factor I receptors. , 1995, Cancer research.

[42]  N. Rao,et al.  The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia. , 2005, Cancer cell.